Overview

Tesofensine (development code NS2330) is a small-molecule triple monoamine reuptake inhibitor originally developed by NeuroSearch in collaboration with Boehringer Ingelheim. Early trials targeted neurodegenerative disease, but efficacy there was limited while marked, dose-related weight loss appeared consistently as an adverse event. The programme was therefore redirected toward obesity.

The pivotal evidence is the phase II TIPO-1 study (Astrup et al., Lancet 2008), a randomised, double-blind, placebo-controlled trial in obese adults across five Danish centres. Over 24 weeks, tesofensine at 0.25, 0.5 and 1.0 mg/day plus diet produced dose-dependent, placebo-subtracted weight loss reaching roughly 9-10% at the higher doses -- substantially greater than sibutramine or rimonabant achieved in comparable trials. An open-label extension (TIPO-4) reported continued weight loss.

The main safety concern is sympathetic activation: tesofensine causes dose-dependent increases in heart rate and blood pressure, plus mood, sleep and gastrointestinal effects. To offset the cardiovascular signal, later development combined tesofensine with the beta-blocker metoprolol as 'Tesomet', studied in hypothalamic obesity and other conditions. Tesofensine remains investigational and is not approved by the FDA or EMA; it is not a peptide but is often catalogued alongside metabolic compounds.

Mechanism of Action

By inhibiting the noradrenaline, dopamine and serotonin transporters, tesofensine amplifies hypothalamic and mesolimbic monoamine tone that governs food intake and reward. Preclinical work suggests appetite suppression is driven substantially by increased dopaminergic and noradrenergic signalling. Because these same pathways drive sympathetic outflow, elevations in heart rate and blood pressure are mechanism-linked rather than incidental, which motivated the beta-blocker co-formulation strategy.

Reconstitution Calculator

Safety Profile

Safety Profile: Tesofensine

Common Side Effects

• Dry mouth, insomnia, and constipation are the most frequently reported adverse effects in clinical trials
• Increased heart rate (mean increase of 7–8 bpm) and elevated blood pressure observed in dose-dependent fashion
• Nausea, diarrhea, and abdominal discomfort
• Headache, dizziness, and mood changes including irritability and anxiety
• Reduced appetite (pharmacological effect, but may become excessive)

Serious Adverse Effects

• Cardiovascular effects: sustained elevations in heart rate and blood pressure at higher doses (0.5–1.0 mg/day) raise concern for long-term cardiovascular safety; tachycardia and hypertension were dose-limiting in Phase II/III trials
• Psychiatric adverse effects including depression, anxiety, suicidal ideation, and insomnia at higher doses; relates to its triple monoamine reuptake inhibition (serotonin, norepinephrine, dopamine)
• Risk of serotonin syndrome when combined with other serotonergic agents
• Potential for abuse and dependence due to dopamine reuptake inhibition, though clinical data suggest lower abuse potential than amphetamines
• QTc prolongation has not been definitively established but cardiovascular monitoring is recommended

Contraindications

• Known hypersensitivity to tesofensine or excipients
• Uncontrolled hypertension or significant cardiovascular disease (coronary artery disease, heart failure, arrhythmias)
• History of stroke or transient ischemic attack
• Concurrent use of MAO inhibitors (risk of hypertensive crisis and serotonin syndrome; washout of at least 14 days required)
• Glaucoma (mydriatic effects possible due to noradrenergic activity)
• Pregnancy and lactation (no human safety data; animal studies showed developmental toxicity)
• History of severe psychiatric disorders including major depression with suicidal ideation, bipolar disorder, or psychosis

Drug Interactions

• MAO inhibitors (phenelzine, tranylcypromine, selegiline): Contraindicated; risk of hypertensive crisis and serotonin syndrome
• Serotonergic drugs (SSRIs, SNRIs, triptans, tramadol): Increased risk of serotonin syndrome due to serotonin reuptake inhibition
• Sympathomimetics (pseudoephedrine, amphetamines): Additive cardiovascular effects; avoid concurrent use
• Antihypertensives: May partially counteract blood pressure effects; dose adjustments may be needed
• CYP3A4 inhibitors: Tesofensine is metabolized via CYP3A4; inhibitors may increase plasma levels

Population-Specific Considerations

• Elderly: Increased cardiovascular risk; not recommended without careful cardiac evaluation
• Pediatric: No safety or efficacy data; not approved for use in children
• Obese patients: Primary studied population (Phase II/III); significant weight loss (10–13% at 0.5 mg) but cardiovascular concerns limited further development
• Cardiac patients: Contraindicated in patients with significant cardiovascular disease
• Psychiatric patients: Monitor closely for mood changes, anxiety, and suicidal ideation

Pharmacokinetic Profile